Phage therapy program
PHAXIAM Therapeutics / former Pherecydes pipeline
| Status | Historical/inactive |
|---|---|
| Type | Company |
| Location | Lyon / historical Nantes activity; France |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | PHAXIAM announced judicial liquidation in June 2025; do not offer its former access program as current. |
|---|---|
| Areas of work | Historical S. aureus, E. coli and P. aeruginosa clinical phage development, including prosthetic joint infection and burn trials. |
| International access | No current access commitment from the liquidated entity established. |
What to confirm
- PHAGENIX is recorded separately; legal asset transfer or full successor access policy was not verified.
- Updated trial sponsor names alone do not prove ongoing operations of PHAXIAM.
Related studies(3)
PHAGOBURN
Ended
Recorded program–study link. Website
PhagoDAIRI
Ended
Recorded program–study link. Website
GLORIA
Not yet recruiting
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
- PHAXIAM issuer liquidation announcement
- PHAXIAM liquidation release on PHAGENIX archive
- CORDIS PHAGOBURN
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | eu-phaxiam-pherecydes |
|---|